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Background-—Genomewide association studies have identiﬁed several loci associated with atrial ﬁbrillation (AF) and have been
reportedly associated with response to catheter ablation for AF in patients of European ancestry; however, associations between
top susceptibility loci and AF recurrence after ablation have not been examined in Asian populations. We examined whether the top
single nucleotide polymorphisms (SNPs) at chromosomes 4q25 (PITX2), 16q22 (ZFHX3), and 1q21 (KCNN3) were associated with
AF in a Korean population and whether these SNPs were associated with clinical outcomes after catheter ablation for AF.
Methods and Results-—We determined the association between 4 SNPs and AF in 1068 AF patients who underwent catheter
ablation (74.6% male, aged 57.510.9 years, 67.9% paroxysmal AF) and 1068 age- and sex-matched controls. The SNPs at the
PITX2 and ZFHX3 loci, but not the KCNN3 locus, were signiﬁcantly associated with AF (PITX2/rs6843082_G: odds ratio 3.41, 95%
CI 2.55 to 4.55, P=1.3291016; PITX2/rs2200733_T: odds ratio 2.05, 95% CI 1.66 to 2.53, P=2.2091011; ZFHX3/
rs2106261_A: odds ratio 2.33, 95% CI 1.87 to 2.91, P=3.7591014; KCNN3/rs13376333_T: odds ratio 1.74, 95% CI 0.93 to
3.25, P=0.085). Among those patients who underwent catheter ablation for AF, none of the top AF-associated SNPs were
associated with long-term clinical recurrence of AF after catheter ablation.
Conclusions-—SNPs at the PITX2 and ZFHX3 loci were strongly associated with AF in Korean patients. In contrast to prior reports,
none of the 4 top AF-susceptibility SNPs predicted clinical recurrence after catheter ablation. ( J Am Heart Assoc. 2015;4:
e002046 doi: 10.1161/JAHA.115.002046)
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A trial ﬁbrillation (AF) is the most commonly foundsustained arrhythmia, with a lifetime risk of 25%.1 Risk
factors include advancing age, hypertension, structural heart
disease, and congestive heart failure, yet a subset of younger
persons develop AF in the absence of established risk factors.
Genetic factors play an important role in the pathogenesis of
AF. Parental history of AF increases risk of AF by 1.4 to 1.9
times.2,3 Familial cases of AF underscore a genetic basis for
disease,4 and research has implicated mutations and poly-
morphisms in the development of AF.5
Recently, several common genetic variants have been
shown to be associated with AF in genomewide association
studies performed in populations of European ancestry6–10;
however, ethnic differences exist in the frequency of
AF-related single nucleotide polymorphisms (SNPs) between
European and Asian populations,11,12 and thus the rela-
tionship between these SNPs and AF in non-European
populations remains unclear. Furthermore, despite the
identiﬁcation of these AF-associated loci, data regarding
the association between variants at these loci and clinical
outcomes remain limited. Some reports suggested that
these variants were associated with an increased risk of
AF recurrence after a radiofrequency catheter ablation
(RFCA),13–15 a common therapy in symptomatic patients
with lone AF. These reports, however, were conducted in
patients of European ancestry, and the associations between
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genetic variants and responses to RFCA in other ancestral
groups remain unclear.
The goal of the current study was 2-fold. First, we sought
to determine whether the top 4 AF SNPs identiﬁed in
European patients were also associated with AF in Korean
patients. These SNPs reside on chromosomes 4q25 (PITX2
locus), 16q22 (ZFHX3 locus), and 1q21 (KCNN3 locus).
Second, we examined whether these AF SNPs were associ-
ated with AF recurrence after RFCA.
Methods
Patient Inclusion
The study protocol was approved by the institutional review
board of Severance Cardiovascular Hospital, Yonsei University
Health System, and adhered to the Declaration of Helsinki.
This study is registered at ClinicalTrials.gov (identiﬁer
NCT02138695). All 2136 subjects (1068 with AF patients
and 1068 with age- and sex-matched control subjects)
provided written informed consent. All AF patients who
underwent RFCA were included in the Yonsei AF Ablation
Cohort registry. The exclusion criteria of this study were as
follows: (1) permanent AF refractory to electrical cardiover-
sion, (2) AF with valvular disease, (3) structural heart disease
other than left ventricular hypertrophy, and (4) prior AF
ablation. Age- and sex-matched control DNA was obtained
from the Korea Centers for Disease Control and Prevention,
National Biobank of Korea (KOBB-2012-00).16,17 All control
subjects had a 12-lead electrocardiogram to exclude the
presence of AF.
SNP Selection and Genotyping
We evaluated selected SNPs from the top 3 AF-associated
genetic loci in European patients from the meta-analysis of
genomewide association studies reported by Ellinor and
colleagues in 2012 and in other previous papers.6,10,18
Speciﬁcally, we selected the top variant or a proxy SNP at
each locus. For the locus at PITX2, the top SNP reported was
rs6817105,6 and the SNP rs2200733 is a perfect proxy for
this SNP (r2=1.0). Because SNP rs6843082 has also been
reported to be strongly associated with AF10 and is in only
modest linkage disequilibrium with rs6817105, we included
this SNP in our analyses (r2=0.434). For the locus at ZFHX3
on chromosome 16q22, the top SNP selected was
rs2106261. At the KCNN3 locus on chromosome 1q21, the
top SNP reported was rs6666258,6 and we selected a perfect
proxy for genotyping: SNP rs13376333 (r2=1.0).
We used whole blood samples for DNA extraction and
genetic analyses. The SNPs were genotyped using validated
TaqMan assays (Applied Biosystems, Life Technologies).
Polymerase chain reaction product was ampliﬁed using
0.9 lm each of the forward and reverse primers, 0.2 lm
each of the ﬂuoresce in amidite and VIC minor groove binder
sequence–speciﬁc probes, 3 ng DNA, 5.0 mmol/L MgCl2,
and 19 TaqMan Universal PCR Master Mix containing
AmpliTaq gold DNA polymerase in a 5.5-lL reaction volume.
All SNPs had a call rate of >99%.
Radiofrequency Catheter Ablation
During the procedure, intracardiac electrograms were
recorded using a Prucka CardioLab electrophysiology system
(General Electric Health Care System Inc). Ablation was
guided by 3-dimensional electroanatomical mapping (NavX
system; St. Jude Medical Inc). An open irrigation 3.5-mm-tip
deﬂectable catheter (Celsius, Johnson & Johnson Inc; Cool
Flex, St. Jude Medical Inc; 30 to 35 W; 47°C) was used for
RFCA (Stockert generator; Biosense Webster Inc). All patients
initially underwent circumferential pulmonary vein (PV) isola-
tion and cavotricuspid isthmus ablation. For patients with
persistent AF, we added a roof line, posterior inferior line, and
anterior line19 as a standard lesion set. At the operator’s
discretion, additional ablations were delivered to the superior
vena cava, non-PV foci, or regions of complex fractionated
electrograms. We conﬁrmed the PV isolation by both entrance
and exit block and rechecked it under an isoproterenol
infusion before ﬁnishing the procedure. In addition, we
attempted to reinduce AF by isoproterenol infusion with rapid
atrial pacing before ﬁnishing the procedure. The end point of
our procedure was deﬁned as no immediate recurrence of AF
after cardioversion while receiving an isoproterenol infusion (5
to 10 lg/min). If there was immediate recurrence of AF after
cardioversion, we then ablated these non-PV foci.
Postablation Management and Follow-up
Patients were seen in the outpatient clinic at 1, 3, 6, and
12 months and then every 6 months thereafter or whenever
symptoms occurred after RFCA. An electrocardiogram was
performed on every visit. A 24- or 48-hour Holter recording
and/or event recorder was obtained at the 3- and 6-month
visits as well as every 6 months afterward in accordance with
the 2012 Heart Rhythm Society, European Heart Rhythm
Association, and European Cardiac Arrhythmia Society expert
consensus statement guidelines.20 Whenever patients
reported symptoms of palpitations, Holter monitor or event
monitor recordings were obtained and evaluated for possible
arrhythmia recurrences. We deﬁned recurrence of AF as any
episode of AF or atrial tachycardia of at least 30 seconds in
duration.21 Early recurrence was deﬁned as having a docu-
mented AF electrocardiogram within 3 months after ablation.
Clinical recurrence was deﬁned as (1) any documented
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recurrence of AF after 3 months21 or (2) the initiation of an
antiarrhythmic medication for AF.
Statistical Analyses
Odds ratios (ORs) were calculated using logistic regression
with an additive genetic model. In case-only analysis, multiple
parameters including clinical features and echocardiography
parameters were compared depending on genotype distribu-
tion. Univariate analysis was performed for continuous
variables using the t test and for nominal variables using
the chi-square test. The log-rank test with Bonferroni
correction for multiplicity of comparisons was applied to
control the type 1 error. Multivariable Cox regression
analyses were conducted to evaluate the associations
between genetic variants and AF recurrence, with adjustment
for age, sex, left atrium size, AF subtype (persistent AF), and
early recurrence (≤3 months). Cases and controls were
matched using the variables age and sex to reduce
confounding effects. Conditional logistic regression models
were used to assess the association between each SNP and
AF risk to take matching situation into account. Potential
confounding factors that were statistically signiﬁcant at
P<0.05 in the univariate analysis were included in the ﬁnal
analysis. ORs and 95% CIs were estimated using conditional
logistic regression analysis with adjustments for potential
confounding factors, body mass index, hypertension, diabetic
mellitus, and congestive heart failure. Additional analyses
were performed in 4 different subgroups. All statistical
analyses were performed using SPSS version 19.0 (IBM
Corp).
Results
Baseline characteristics of the study population are summa-
rized in Table 1. We studied 1068 patients who underwent an
AF ablation and 1068 controls who were matched on the
basis of age and sex. The mean age of our study population
was 57.511.2 years, and 74.6% of participants were male.
As expected, the AF group had a higher prevalence of
hypertension, diabetes mellitus, congestive heart failure,
stroke, and coronary artery disease than the control group.
To exclude the possible confounding effects caused by the
imbalance of disease prevalence between cases and controls,
we sequentially performed subgroup analyses excluding
patients with the following risk factors: (1) hypertension; (2)
diabetes mellitus; (3) congestive heart failure; and (4) strokes,
Table 1. Baseline Characteristics of the Study Population
AF (n=1068) Controls (n=1068)
Age, y 57.510.9 57.511.5
Male sex, % 74.6 74.6
PAF, % 67.9 —
Body mass index, kg/m2† 24.73.2 23.63.1*
Hypertension 510 (47.8) 19 (1.8%)*
Diabetes mellitus 139 (13.0) 14 (1.3%)*
Congestive heart failure 70 (6.6) 1 (0.1%)*
Stroke 106 (9.9) 0 (0%)*
Coronary artery disease 136 (12.7) 0 (0%)*
CHADS2 score 0.951.09 —
Echocardiography
LA dimension, mm 41.66.5 —
LA volume index 35.012.3
LVEF, % 63.19.0 —
E/Em 9.75.1 —
LVEDD, mm 49.36.6 —
LVESD, mm 33.25.8 —
LVMI, g/m2 75.341.2 —
Early recurrence, % 28.5 —
Clinical recurrence, % 19.0 —
Data are shown as meanSD or n (%), except as noted. AF (n=1068) and control
(n=1068). For the CHADS2 score, 1 point is given for congestive heart failure,
hypertension, age >75 years, and diabetes mellitus; 2 points are given for previous
stroke and transient ischemic attack. AF indicates atrial ﬁbrillation; LA, left atrium;
LVEDD, left ventricular end-diastolic dimension; LVEF, left ventricular ejection fraction;
LVESD, left ventricular end-systolic dimension; LVMI, left ventricular mass index; PAF,
paroxysmal atrial ﬁbrillation.
*P<0.001 compared with AF.
†16% of body mass index in controls are missing.
Table 2. Association Between AF and SNPs From 3 Known AF Loci
Nearest Gene SNP Chr Position Minor Allele/Major Allele MAF AF Associated Allele OR 95% CI P Value*
PITX2 rs6843082 4 111937516 A/G 0.204 G 3.41 2.55 to 4.55 1.3291016
PITX2 rs2200733 4 111929618 C/T 0.394 T 2.05 1.66 to 2.53 2.2091011
ZFHX3 rs2106261 16 71609121 A/G 0.395 A 2.33 1.87 to 2.91 3.7591014
KCNN3 rs13376333 1 153080977 T/C 0.019 T 1.74 0.93 to 3.25 0.085
AF indicates atrial ﬁbrillation; Chr, chromosome; MAF, minor allele frequency; OR, odds ratio; SNPs, single nucleotide polymorphisms.
*P value was calculated by using conditional logistic regression after adjusting for body mass index, hypertension, diabetes mellitus, and congestive heart failure.
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coronary artery disease, and congestive heart failure simul-
taneously. All subgroup analyses were performed by using
multivariable logistic regression, adjusting for age, sex, body
mass index, hypertension, diabetic mellitus, and congestive
heart failure, as appropriate, and the results were consistent
(Table S1).
PITX2 and ZFHX3 Were Strongly Associated With
AF in Korean Patients
We found that 2 of the 3 knownAF-associated loci were strongly
associated with AF in Korean patients (Table 2). Two variants at
the PITX2 locus and 1 at the ZFHX3 locus were signiﬁcantly
associated with AF (rs6843082_G: OR 3.41, 95% CI 2.55 to
4.55, P=1.3291016; rs2200733_T: OR 2.05, 95% CI 1.66
to 2.53, P=2.2091011; rs2106261_A: OR 2.33, 95% CI 1.87
to 2.91, P=3.7591014) In contrast, genetic variants at the
KCNN3 locus were not associated with AF in Korean patients
(rs13376333_T: OR 1.74, 95% CI 0.93 to 3.25, P=0.085).
Interestingly, the frequency of the AF risk allele at this locus
(rs13376333_T) was very low in the Korean population, at only
1.9% compared with 29.5% in European patients.10
Relationship Between AF-Risk SNPs and Baseline
Clinical Characteristics of Patients Undergoing AF
Ablation
Next we sought to determine whether any baseline differ-
ences existed in an extensive set of clinical and echocardio-
graphic parameters based on AF genotype (Table 3). Among
the 1068 AF ablation patients, the only notable difference was
that carriers of the AF-associated risk allele for SNP
rs6843082 on chromosome 4q25 were younger (50.815.3
versus 59.011.1, P=0.005).
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Figure. Kaplan–Meier curve showing relationship among recurrence and risk alleles of
rs6843082 in PITX2 (A), rs2200733 in PITX2 (B), rs2106261 in ZFHX3 (C), and rs13376333
in KCNN3 (D). AF indicates atrial ﬁbrillation.
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Relationship Between AF Genotype and
Outcomes After AF Ablation
After ablation, 304 patients (28.5%) had early recurrence
during the 3-month blanking period. We did not observe any
signiﬁcant associations between AF-risk SNPs and early AF
recurrence. During 18.313.9 months (range 0 to
55 months) of follow-up, 203 patients (19.0%) had a clinical
recurrence >3 months from RFCA. Figure displays the
freedom from AF recurrence for each of the 4 SNPs. None
of the 4 SNPs were associated with a long-term clinical
recurrence after RFCA (Table 4).
Discussion
In a well-characterized cohort of >1000 Korean patients with
nonvalvular AF, we observed that 2 of the 3 main AF
susceptibility signals discovered in European patients (chro-
mosomes 4q25 [PITX2] and 16q22 [ZFHX3]) were similarly
associated with AF, supporting a shared genetic basis for AF
that transcends ancestry. Second, and in contrast to prior
reports,13,14 we did not observe any signiﬁcant associations
between these top 4 AF susceptibility loci and AF recurrence
following catheter ablation.
Interestingly, the AF risk allele at 1q21 was not associated
with AF; however, the frequency of this variant in the Korean
population was rare. Large-scale genomewide association
studies showed the association of SNPs in PITX2, ZFHX3, and
KCNN3 with AF in patients of European ancestry, and the
results were replicated in a Japanese study.6 In Table 5, we
summarized the published results of these 4 AF variants in
patients of Asian descent. We noted that most published
studies were smaller and studied only 1 or 2 of the top
AF variants. Although SNPs at PITX2 and ZFHX3 were
consistently associated with AF, there was less consistency
among the studies at the KCNN3 locus. The lack of replication
of the association at the KCNN3 locus may be due to the
rarity of this risk allele among those of Asian descent. In
Korean patients, the risk allele was quite rare, with a minor
Table 4. Association Between Candidate Genes (SNPs) and
Clinical Recurrence of AF Using Cox Regression Model
Gene/SNP
Adjusted*
HR 95% CI P Value
PITX2/rs6843082_G 0.84 0.61 to 1.15 0.280
PITX2/rs2200733_T 1.01 0.80 to 1.26 0.963
ZFHX3/rs2106261_A 0.86 0.71 to 1.04 0.128
KCNN3/rs13376333_T 0.72 0.38 to 1.36 0.308
AF indicates atrial ﬁbrillation; HR, hazard ratio; SNPs, single nucleotide polymorphisms.
*Adjusted for sex, age, left atrium size, AF subtype (persistent AF), and early recurrence
(≤3 months).
Table 5. Summary of Association Results for the 3 AF Loci
Ethnicity European6 Japanese6 Hong Kong9 Chinese11 Taiwanese12 Hong Kong22 Chinese23 Chinese24 Korean
Total Number
(AF Patients) 59 133 (6707) 4193 (843) 3048 (285) 2097 (650) 428 (214) 3169 (333) 1234 (383) 1593 (597) 2136 (1068)
PITX2
OR 1.64 1.84 1.42 1.81 3.06
95% CI 1.55 to 1.73 1.59 to 2.13 1.16 to 1.73 1.21 to 3.20 2.59 to 3.61
P value 1.891074 3.791017 0.00064 3.791011 4.391014
SNP rs6817105 rs2634073 rs2200733 rs2200733 rs6843082
ZFHX3
OR 1.24 0.8 1.05 1.32 1.71 2.03
95% CI 1.17 to 1.30 0.71 to 0.91 0.87 to 1.26 1.15 to 1.51 1.46 to 2.00 1.79 to 2.31
P value 3.291016 6.89104 0.63 1.979104 1.991011 5.391014
SNP rs2106261 rs12932445 rs7193343 rs2106261 rs2106261 rs2106261
KCNN3
OR 1.18 1.46 1.24 3.02 1.38
95% CI 1.13 to 1.23 0.85 to 2.51 0.88 to 1.75 1.54 to 6.29 0.89 to 2.14
P value 2.091014 0.17 0.333 <0.001 0.152
SNP rs6666258 rs7514452 rs13376333 rs13376333 rs13376333
AF indicates atrial ﬁbrillation; OR, odds ratio; SNP, single nucleotide polymorphism.
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allele frequency of only 1.9%. Similarly, in Japanese and
Chinese studies, this variant had a minor allele frequency of
1.5% and 4%, respectively. In contrast, European and
Taiwanese populations had high prevalence of the AF risk
allele (29.6% and 8.6%, respectively). Our ﬁndings highlight
the variability in this KCNN3 AF risk allele, even among those
of Asian descent. Our results also demonstrate the need for
large-scale genetic studies in speciﬁc Asian subgroups to
identify this and other regions uniquely associated with AF.
The ﬁrst identiﬁcation of common genetic variants dates to
2007, yet data on the clinical utility of these variants remains
relatively limited.25 Investigators have examined the risk of
AF after cardioversion,26 the initiation of antiarrhythmic
medication,27 and PV isolation ablation procedures.13,14 In
our study of >1000 Korean patients who underwent PV
ablation, we did not observe any signiﬁcant associations
between the AF risk alleles on chromosomes 4q25, 16q22, or
1q21 and recurrent AF after catheter ablation. Our ﬁndings
are in contrast to the recent observations in 2 studies of
patients with Europeans ancestry (Table 6).13,14 Many poten-
tial causes could underlie the discordant results observed
between Asian and European populations. First, our results
may point to a speciﬁc racial difference in the associations
between AF genetic data and clinical recurrence after RFCA.
It is possible that the genetic variants that we considered in
Korean patients are only proxies rather than the truly
causative SNPs at these loci. Second, because our study is
nearly 3 times larger than the prior studies, it is possible that
the ﬁndings in European patients reﬂected a relatively smaller
sample size. Finally, the differences may also be due to
technical variability of RFCA, surveillance for AF, or the length
of the follow-up period among the studies. Ultimately, further
large-scale multicenter studies will help resolve each of these
issues.
Strengths of our study include the largest cohort of patients
of Asian descent described to date, a well-characterized
ablation population with detailed phenotypic data, and a
standardized clinical protocol for follow-up after ablation. Our
study was also subject to a number of potential limitations.
First, we excluded patients with signiﬁcant structural heart
disease. Second, because we studied a Korean population, our
results may not be generalizable to other races and ethnicities.
This observational study included a highly selected group of
patients referred for Yonsei AF Ablation Cohort; therefore, the
results cannot be generalized to the entire AF population or to
other ethnicities. The lack of association of the polymorphism
to the recurrence of AF after ablationmight be related to the low
frequency of the variant in the selected population, a small
effect of polymorphisms, heterogeneity of the population with
varying underlying substrate, variable ablative techniques used,
and follow-up, despite the relatively consistent protocols for
inclusion, ablation, and follow-up.
Conclusions
Genetic variants at the PITX2 and ZFHX3 loci were strongly
associated with AF among Korean patients, whereas there
Table 6. Summary of AF Genetic Studies Related to AF Catheter Ablation
N Age Male PAF Race
End Point
SNP
Closest
Gene
Late Recurrence of AF
Early
Recurrence
of AF
Late Recurrence
of AF HR (95% CI)
P
Value
Husser14 195 5612 73% 78% European Within 7 days Between 3 and
6 months
rs10033464_T PITX2 2.82 (1.29 to
6.15)*
0.009
rs2200733_T PITX2 2.46 (1.06 to
5.69)*
0.036
Shoemaker13 311 60 (52
to 66)
72% 47% European N/A After the 3-month
postablation
blanking period
rs2200733_T PITX2 0.76 (0.6 to
0.95)†
0.016
rs10033464_T PITX2 N/A 0.97‡
Current
study
1068 5811 75% 68% Asian Within the
3-month
postablation
period
After the 3-month
postablation
blanking period
rs6843082_G PITX2 0.84 (0.61 to
1.15)
0.280
rs2200733_T PITX2 1.01 (0.80 to
1.26)
0.963
rs2106261_T ZFHX3 0.86 (0.71 to
1.04)
0.128
AF indicates atrial ﬁbrillation; HR, hazard ratio; N/A, not available due to lack of data in published paper13; PAF, paroxysmal atrial ﬁbrillation; SNP, single nucleotide polymorphism.
*Odds ratio.
†Survival time ratio.
‡Log-rank test.
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was no association at the KCNN3 locus. The clinical outcomes
after a catheter ablation for AF could not be predicted by
genetic variants in Korean patients.
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